Clinical Trial Update: Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial results report the efficacy and safety of fingolimod (FTY720) in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED